Form 4: IO Biotech Director Christian Elling Granted 35,144 Stock Options

IO Biotech, Inc. Director Christian E. Elling was granted 35,144 stock options with an exercise price of $1.50, vesting on June 5, 2026.

Summary

• Christian E. Elling, a Director of IO Biotech, Inc. (IOBT), was granted 35,144 stock options.
• The options have an exercise price of $1.50 per share.
• The transaction date for this grant was June 5, 2025.
• These options are scheduled to vest on June 5, 2026, contingent upon Mr. Elling's continued service.
• The options have an expiration date of June 5, 2035.
• A 100% acceleration of vesting will occur upon a change of control.
• The options are directly beneficially owned by Mr. Elling.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates a director's continued commitment and alignment with shareholder interests through equity compensation, which is a standard and generally positive practice.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term value creation.
• The options include a change of control acceleration clause, providing a potential benefit to the director in such an event.

Risks

• The value of the stock options is dependent on the future market price of IO Biotech's common stock; if the stock price does not exceed the exercise price of $1.50, the options may expire worthless.
• Vesting of the options is subject to the reporting person's continued service, meaning the options could be forfeited if service terminates before the vesting date.

Future Outlook

The stock options granted to Director Christian E. Elling are set to vest on June 5, 2026, contingent on his continued service, providing a future incentive tied to the company's performance. The options will expire on June 5, 2035, allowing a long window for potential exercise if the stock price appreciates.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity grant, common in the biotechnology industry and other sectors, as a form of executive and director compensation designed to align interests with shareholders. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The grant of stock options to Christian E. Elling, a Director of IO Biotech, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder interests, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest on June 5, 2026, subject to the director's continued service.
• The director may choose to exercise the options at any point after vesting and before the expiration date of June 5, 2035, assuming the stock price is above the exercise price.

Key Dates

Keywords

IO Biotech, IOBT, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Vesting, Biotechnology